Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.
Ticker SymbolDNA
Company nameGinkgo Bioworks Holdings Inc
IPO dateApr 19, 2021
CEODr. Jason Kelly
Number of employees834
Security typeOrdinary Share
Fiscal year-endApr 19
Address27 Drydock Avenue
CityBOSTON
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code02210
Phone18774425362
Websitehttps://investors.ginkgobioworks.com/
Ticker SymbolDNA
IPO dateApr 19, 2021
CEODr. Jason Kelly
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data